Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

October 05, 2010 09:25 ET

Global Health Ventures Today Announces Retention of International Monetary as Its Investor Relations & Strategic Advisory Firm

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 5, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company"), a Specialty Pharma with focus on sublingual drug delivery, is pleased to announce that, it has engaged International Monetary ("IM") as its investor relations and strategic advisory firm to provide investor relations services (IR), public relations services (PR), and advise the Company's management on other strategic decisions including merger and acquisitions (M&A).

International Monetary (IM) is headquartered in Newport Beach, California, and is one of the premier investment banking consulting firms in the United States catering specifically to small-cap and mid-cap public companies. With its team of professionals serving its corporate clients, IM has the experience and resources to quickly facilitate lucrative strategic partners/alliances for the Company, and to work in achieving a more deserved market capitalization through its proprietary investor relations services to the investment community.

"With our state of the art technology in drug delivery and having two products in various stage of clinical trials, we believe that by working with a powerful investment banking consultant like IM, we should have little problem in obtaining a meaningful strategic partner/alliance for our company and getting the capital appreciation it deserves," said Dr. Hassan Salari, Global Health President & CEO.

About Global Health Ventures

Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. Our second drug "Relax-B" is also under development in Canada for anxiety. Our third drug will be the anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information